Novel Prognostic Personalized Biomarker and Therapeutic Target in Blood Cancer Related Fibrosis

The objective of this ERC Proof of Concept is to demonstrate the clinical application and commercial viability of a specific driver of the innate immune system as a novel predictive biomarker and as a novel therapeutic target for the diagnosis and treatment of bone marrow fibrosis related to blood cancer.

This proposed project builds upon recent findings of my deFiber ERC Starting Grant (Stg) project, where we identified this danger-associated molecular pattern complex as exactly as such a prognostic and predictive biomarker and importantly showed that targeting with a small molecular, oral, anti-cancer inhibitor reduced fibrosis but also the cancer cell burden, in the sense of a targetable biomarker.